CXCR2 and neoplasm: Blocking CXCR1 and CXCR2 with small molecule inhibitor SX-682 significantly abrogated CXCR2+PMN-MDSC tumor accumulation and enhanced the efficacy of both the PD-axis immune checkpoint blockade and adoptive cell transfer of engineered T cells [92].